Abeona Therapeutics (ABEO) stock price, revenue, and financials

Abeona Therapeutics market cap is $120.5 m, and annual revenue was $10 m in FY 2020

$120.5 M

ABEO Mkt cap, 23-Sept-2021

$10 M

Abeona Therapeutics Revenue FY, 2020
Abeona Therapeutics Net income (FY, 2020)-84.2 M
Abeona Therapeutics EBIT (FY, 2020)-81.4 M
Abeona Therapeutics Cash, 31-Dec-202012.6 M
Abeona Therapeutics EV116.6 M
Get notified regarding key financial metrics and revenue changes at Abeona TherapeuticsLearn more
Banner background

Abeona Therapeutics Revenue Breakdown

Embed Graph

Abeona Therapeutics revenue breakdown by business segment: 6.7% from Royalties and 93.3% from Foundation Revenues

Abeona Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

837.0k3.0m10.0m

Revenue growth, %

258%

R&D expense

17.0m38.7m48.6m30.1m

General and administrative expense

10.9m20.1m20.7m23.8m

Operating expense total

28.7m61.2m77.1m86.8m

Depreciation and amortization

741.0k2.4m7.8m4.6m

EBIT

(27.8m)(58.2m)(77.1m)(81.4m)

EBIT margin, %

(3326%)(1940%)(814%)

Interest expense

8.0k11.0k400.0k

Investment income

525.0k1.5m1.2m

Net Income

(27.3m)(56.7m)(76.3m)(84.2m)

EPS

(0.7)(1.2)(1.5)

Abeona Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

137.8m18.8m129.3m12.6m

Accounts Receivable

107.0k81.0k

Prepaid Expenses

2.7m3.8m3.1m2.7m

Current Assets

140.6m88.9m132.4m97.7m

PP&E

1.4m9.4m13.2m11.3m

Goodwill

32.5m32.5m32.5m32.5m

Total Assets

178.8m174.4m223.4m151.2m

Accounts Payable

2.4m6.1m3.8m4.7m

Short-term debt

1.7m2.0m

Current Liabilities

5.6m20.4m38.7m42.0m

Long-term debt

6.3m6.7m

Total Debt

8.0m8.7m

Total Liabilities

8.7m40.4m45.0m48.6m

Common Stock

469.0k479.0k836.0k961.0k

Additional Paid-in Capital

529.4m543.8m664.1m672.3m

Retained Earnings

(359.8m)(410.2m)(486.5m)(570.7m)

Total Equity

170.1m134.0m178.4m102.6m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.3 x1.3 x1.5 x

Abeona Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.3m)(56.7m)(76.3m)(84.2m)

Depreciation and Amortization

741.0k2.4m7.8m4.6m

Accounts Receivable

17.0k26.0k81.0k

Accounts Payable

(1.3m)7.7m(1.7m)

Cash From Operating Activities

(22.9m)(39.1m)(62.8m)(35.0m)

Purchases of PP&E

(860.0k)(9.2m)(6.3m)(1.3m)

Cash From Investing Activities

(860.0k)(85.1m)60.0m(83.7m)

Cash From Financing Activities

92.4m5.5m113.9m1.9m

Net Change in Cash

68.6m(118.7m)111.1m(116.8m)

Interest Paid

8.0k11.0k

Abeona Therapeutics Ratios

USDQ1, 2017

Revenue/Employee

9.8k

Financial Leverage

1.1 x

Abeona Therapeutics Operating Metrics

FY, 2018FY, 2019

Product Candidates

88

Facility Space, sq. ft.

55.8 k57.4 k

Manufacturing Space, sq. ft.

43.7 k45.3 k